FDA Approves First Generic Lenacapavir for HIV Prevention at $40 Per Year

The U.S. Food and Drug Administration granted tentative approval on November 2 to the first generic version of injectable lenacapavir for HIV prevention. Dr. Reddy's Laboratories of Hyderabad, India, developed the twice-yearly shot. It will cost $40 per person per year in 120 low- and middle-income countries covered by Gilead Sciences' voluntary licensing program.

Gilead's originator product, marketed as Yeztugo in the United States, received approval in June 2025. Its list price stands at $28,218 per year. The generic approval arrived 16 months later. Unitaid, the Clinton Health Access Initiative, and Wits RHI supported the accelerated timeline through technical and regulatory assistance. More than 125,000 people in Africa have already started on the originator version.

Tentative approval means the generic cannot be sold inside the United States while the originator patent remains in force. It does allow purchase by the U.S. government for use abroad and often speeds approvals by other regulators and the World Health Organization. First supplies are expected to reach countries before the end of 2026, with broader availability in 2027. Zambia is among the early recipients.

Lenacapavir is a capsid inhibitor that acts at multiple stages of the HIV lifecycle. The injectable form provides protection for six months per dose. Daily oral pre-exposure prophylaxis pills currently cost roughly the same $40 annual figure in many programs. The long-acting option reduces the need for daily adherence and clinic visits in settings where travel and supply chains are difficult.

Neil Buddy Shah, CEO of the Clinton Health Access Initiative, stated that more than 125,000 people in Africa have already started on lenacapavir and that the approval brings the $40 price closer for millions more. Deepak Sapra of Dr. Reddy's described the regulatory path as one of the fastest for a major HIV innovation. The company combined prevention and treatment indications in a single application under the FDA's 505(b)(2) pathway and received priority review.

Gilead granted the voluntary license to Dr. Reddy's in October 2024. The September 2025 pricing agreement locked in the $40 figure before final regulatory clearance. The process shortened a timeline that often stretches a decade between originator approval and generic entry. Countries receiving the product will still need to complete their own registrations, but the FDA step removes a major barrier for programs funded by PEPFAR and other donors.

The price differential is stark. At $28,218 in the U.S. market versus $40 in the licensed countries, the generic expands reach where the epidemic remains concentrated. Unitaid aims for initial deliveries by World AIDS Day on December 1 in some locations. Scaling production will determine how quickly the full 120-country list can be supplied. Dr. Reddy's has indicated that broader rollout begins in 2027 once manufacturing capacity expands.

Health programs in recipient countries must now plan cold-chain logistics, training for injectors, and demand forecasting. The twice-yearly schedule changes clinic workflows compared with daily pills. Data from the early African adopters will inform those plans. The approval itself does not end the epidemic, but it removes the largest cost barrier for a product that has shown high efficacy in clinical trials. The concrete outcome is a generic injectable available at the same annual cost as existing daily options, delivered on a timeline measured in months rather than years.